{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-089330","form_type":"8-K","ticker":"NVCT","cik":"0001875558","company_name":"Nuvectis Pharma, Inc.","filed_at":"2023-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.958834+00:00","generated_at":"2026-06-11T23:35:10.337904+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Nuvectis Q2 net loss $5.7M; cash $24.6M; NXP900 IND cleared, Phase 1a expected Q3 2023","bullets":["Cash $24.6M at June 30, 2023, up from $20.0M at Dec 31, 2022, enough into H1 2025.","Net loss $5.7M vs $3.6M in Q2 2022; R&D expense $4.3M vs $2.5M.","NXP800 Phase 1b in platinum-resistant ARID1a-mutated ovarian cancer ongoing; data expected Q1 2024.","NXP900 IND cleared by FDA; Phase 1a dose escalation study set to begin in Q3 2023.","Potential NXP800 expansion into cholangiocarcinoma supported by preclinical data."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-089330","json":"https://secwatch.observer/filing/0001104659-23-089330.json","markdown":"https://secwatch.observer/filing/0001104659-23-089330.md","text":"https://secwatch.observer/filing/0001104659-23-089330.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1875558/000110465923089330/0001104659-23-089330-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1875558/000110465923089330/tm2323028d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T23:35:10.337904+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"656c882e26f30649a96efdd085c1aec326aae1d9","claim":"Nuvectis Pharma, Inc. reported the second quarter ended June 30, 2023 results: net income $5.7 million.","evidence_excerpt":"Nuvectis Pharma, Inc. issued a press release to provide a corporate update and to announce its financial results for the second quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1875558/000110465923089330/0001104659-23-089330-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Net income","value":"$5.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"656c882e26f30649a96efdd085c1aec326aae1d9","claim":"Nuvectis Pharma, Inc. reported the second quarter ended June 30, 2023 results: net income $5.7 million.","evidence_excerpt":"The Company's net loss was $5.7 million for the three months ended June 30, 2023, compared to $3.6 million for the three months ended June 30, 2022, an increase of $2.1 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1875558/000110465923089330/0001104659-23-089330-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Net income","value":"$5.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}